Canaccord analyst Edward Nash lowered the firm’s price target on Corcept Therapeutics (CORT) to $137 from $142 and keeps a Buy rating on the shares. The firm noted they reported financial results and business highlights for 2Q25. Korlym product sales revenue was $194.4M for the quarter, slightly higher than the firm’s estimate of $193M, representing an 18.7% Y/Y growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics: Buy Rating Backed by Strategic Growth Initiatives and Promising Product Launches
- Corcept Therapeutics Reports Revenue Growth Amid Rising Expenses
- Corcept Therapeutics reports Q2 EPS 29c, consensus 19c
- Corcept Therapeutics Reports Q2 2025 Financial Results
- Corcept Therapeutics Advances Long-Term Safety Study of Relacorilant for Cushing Syndrome